LiveWire Ergogenics Inc (LVVV)
OTHER OTC:LVVV
Top Page
LiveWire Ergogenics
(OTC:LVVV)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.01
▲(1150.00% Upside)
Action:ReiteratedDate:03/22/26
The score is driven primarily by weak financial performance, highlighted by a severe 2025 revenue collapse, large net loss, and negative shareholders’ equity. Valuation is also challenged by a negative P/E with no dividend yield provided, while technical analysis is neutral due to missing indicators.
Positive Factors
Cannabis-focused holding model
The holding-company model centered on acquiring, developing and operating cannabis cultivation properties provides asset-backed optionality. Owning and operating properties can create diversified revenue levers (leases, operations, JV arrangements) and preserves strategic flexibility over months.
Negative Factors
Severe revenue collapse and volatility
A dramatic fall in sales to roughly $7.8K in 2025 from prior years shows extreme demand or execution deterioration. Such severe revenue volatility undermines predictable cash generation, complicates planning, and materially raises the risk that operations cannot sustainably cover costs or service obligations in the near term.
Read all positive and negative factors
Positive Factors
Negative Factors
Cannabis-focused holding model
The holding-company model centered on acquiring, developing and operating cannabis cultivation properties provides asset-backed optionality. Owning and operating properties can create diversified revenue levers (leases, operations, JV arrangements) and preserves strategic flexibility over months.
Read all positive factors
LiveWire Ergogenics (LVVV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$761.59K
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)172.90
Revenue Growth-81.39%
EPS Growth-100.00%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,903,979,100
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-0.87
Price to Sales (P/S)168.12
P/FCF Ratio-180.19
Enterprise Value/Market Cap4.92
Enterprise Value/Revenue478.06
Enterprise Value/Gross Profit-779.84
Enterprise Value/Ebitda-45.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LiveWire Ergogenics Business Overview & Revenue Model
Company Description
LiveWire Ergogenics Inc. focuses on acquiring, managing, and licensing special purpose real estate properties to produce handcrafted and organically grown cannabis products for medical and recreational adult-use in California. The company is based...
How the Company Makes Money
null...
LiveWire Ergogenics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.83K | 7.83K | 304.12K | 1.63M | 1.94M | 851.20K |
| Gross Profit | -4.80K | -17.44K | 285.16K | 1.59M | 1.80M | 701.55K |
| EBITDA | -82.17K | -157.16K | 322.18K | 1.22M | 1.07M | -2.68M |
| Net Income | -1.17M | -4.78M | 78.72K | 921.58K | 684.12K | -3.43M |
Balance Sheet | ||||||
| Total Assets | 2.63M | 2.26M | 7.96M | 7.74M | 6.27M | 4.52M |
| Cash, Cash Equivalents and Short-Term Investments | 1.67K | 1.48K | 11.27K | 27.87K | 76.38K | 199.95K |
| Total Debt | 3.53M | 3.05M | 3.35M | 3.34M | 3.20M | 2.85M |
| Total Liabilities | 4.16M | 3.78M | 4.70M | 4.62M | 4.24M | 3.61M |
| Stockholders Equity | -1.54M | -1.51M | 3.24M | 3.11M | 2.03M | 912.13K |
Cash Flow | ||||||
| Free Cash Flow | 11.44K | -7.31K | 124.74K | 682.37K | 396.37K | -467.21K |
| Operating Cash Flow | 11.43K | -7.31K | 124.74K | 682.37K | 396.37K | -399.89K |
| Investing Cash Flow | 0.00 | 0.00 | -187.34K | -857.40K | -1.20M | -930.51K |
| Financing Cash Flow | 0.00 | 0.00 | 46.00K | 126.51K | 684.50K | 1.42M |
LiveWire Ergogenics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $5.15M | -0.28 | -203.36% | ― | ― | 90.53% | |
42 Neutral | $1.98M | -0.43 | ― | ― | ― | ― | |
41 Neutral | $761.59K | -0.28 | ― | ― | -81.39% | -100.00% | |
40 Underperform | $404.68K | -2.13 | ― | ― | -8.57% | -52.17% |
* Healthcare Sector Average
LVVV
LiveWire Ergogenics
―
―
―
PRFX
PainReform
2.34
-6.76
-74.29%
MSPR
MSP Recovery
0.03
-9.63
-99.71%
DRMA
Dermata Therapeutics
1.28
-6.78
-84.12%
CERO
CERo Therapeutics Holdings
0.03
-16.69
-99.81%
AKAN
Akanda Corp
0.69
-16.50
-95.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.